Timeline Title

2017

Second-Line Therapy

Previously, TDM-1 was the standard second-line treatment after taxane and trastuzumab. The EMILIA trial demonstrated TDM-1's superiority over lapatinib plus capecitabine.

By Matthew Stenger

This would be a blurb for a video

By The ASCO Post

2018

Third Line Therapy

Previously, TDM-1 was the standard second-line treatment after taxane and trastuzumab. The EMILIA trial demonstrated TDM-1's superiority over lapatinib plus capecitabine.

By Matthew Stenger

This would be a blurb for a video

By The ASCO Post

this is how a section appears with more than 2 items

By Jay Harris

2018

4th Line therapy

Previously, TDM-1 was the standard second-line treatment after taxane and trastuzumab. The EMILIA trial demonstrated TDM-1's superiority over lapatinib plus capecitabine.

By Matthew Stenger

This would be a blurb for a video

By The ASCO Post